CHRS 8-K 2026-01-13

Coherus Oncology, Inc. (CHRS) 8-K dated 2026-01-13 — accession 0001104659-26-003117. This URL is the filing, not the CHRS hub.

Coherus Oncology, Inc. (CHRS) is a biotechnology company listed on US.

Coherus Oncology, Inc. filed a 8-K on 2026-01-13. Accession 0001104659-26-003117.

Cached items: 2.02, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported CHRS revenue for 2026-06-30 was $26.6M. Net income was -$59.0M. CHRS currently screens at market cap $223.7M.

Not investment advice. The CHRS SEC hub lists recent forms. The stock page is the research view.